TTY Biopharm Company Limited reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 1,261.56 million compared to TWD 1,165.52 million a year ago. Revenue was TWD 1,261.56 million compared to TWD 1,165.52 million a year ago. Net income was TWD 308.69 million compared to TWD 284.16 million a year ago. Basic earnings per share from continuing operations was TWD 1.24 compared to TWD 1.14 a year ago. Diluted earnings per share from continuing operations was TWD 1.24 compared to TWD 1.14 a year ago.
For the six months, sales was TWD 2,427.9 million compared to TWD 2,202.63 million a year ago. Revenue was TWD 2,427.9 million compared to TWD 2,202.63 million a year ago. Net income was TWD 547.37 million compared to TWD 511.67 million a year ago. Basic earnings per share from continuing operations was TWD 2.2 compared to TWD 2.06 a year ago. Diluted earnings per share from continuing operations was TWD 2.2 compared to TWD 2.06 a year ago.